KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS® is approved for use in combination with daratumumab plus dexamethasone, dexamethasone or with lenalidomide plus dexamethasone, or isatuximab plus dexamethasone, which are other medicines used to treat multiple myeloma.
The information provided in this section is intended expressly for healthcare professionals in the United States. Click “Yes, I am” to enter if you are a U.S. healthcare professional.
Here you can find answers to some frequently asked questions about KYPROLIS®. Ask your doctor if KYPROLIS® is
right for you.
We know every patient has unique needs. And we’re here to provide financial support information and resources, regardless of your current financial situation or the type of insurance you have.
If you have private or commercial insurance that you get from your employer or buy directly from a health insurance company, you may be eligible for co-pay programs that can help lower the out-of-pocket costs of your prescription.
Amgen® SupportPlus Co-Pay Program
The Amgen SupportPlus Co-Pay Program may help patients with private or commercial insurance lower their out-of-pocket costs.
Learn more about the ways Amgen SupportPlus can help you access your prescribed medication. Visit AmgenSupportPlus.com/copay to learn more.
*Eligibility criteria and program maximums apply. See www.AmgenSupportPlus.com/copay for full Terms and Conditions.
Amgen SupportPlus can provide information about independent nonprofit foundations that may be able to help.*
Call Amgen SupportPlus at (866) 264-2778, Monday–Friday 9:00 AM–8:00 PM ET, to learn more.
*Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides information as a courtesy only.
Amgen Nurse Partners* will be with you along the way to offer support and provide information about resources to help you access your prescribed Amgen medication.
Amgen Nurse Partners can provide support, including guidance on resources that may help lower out-of-pocket medication costs:
Get connected with an Amgen Nurse Partner by enrolling in Amgen SupportPlus.
*Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.
Here are some questions to ask your doctor:
KYPROLIS® is a treatment for adults with relapsed multiple myeloma (multiple myeloma that has returned) or refractory multiple myeloma (multiple myeloma that no longer responds to treatment). It is prescribed in combination with other medicines or alone. You and your doctor will decide which is right for you.
KYPROLIS® is a standard of care* for relapsed or refractory multiple myeloma with over 12 years of clinical experience.
Over 190,000 people in the United States and over 400,000 people worldwide have received KYPROLIS® treatment for their relapsed or refractory multiple myeloma since its approval.†
*A treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by healthcare professionals. Also called best practice, standard medical care, and standard therapy.
†Total KYPROLIS® units (vials) distributed through December 2024 were obtained from the Amgen Finance Electronic Database Warehouse. An estimated total of 191,189 people in the US and 407,630 people worldwide were exposed to KYPROLIS® from launch (July 2012) through December 31, 2024 based on the latest Postmarketing Exposure Estimation report dated January 2025.
KYPROLIS® works in your body by inhibiting, or blocking, myeloma cell proteasomes. This is important because myeloma cells depend on proteasomes to recycle proteins in order to grow and multiply. By blocking proteasomes, KYPROLIS® causes many proteins to build up inside the cells. This way KYPROLIS® results in the death of myeloma cells.
Though KYPROLIS® affects myeloma cells more than normal cells in your body, normal cells may also be affected by treatment.
KYPROLIS® is given as an intravenous (IV) infusion. This is a way to put fluids, including medicine, into your bloodstream through a vein in your body. Your infusion time will range from 10 to 30 minutes depending on your treatment regimen.
Depending on the combination, you will receive KYPROLIS® infusions once per week or 2 back-to-back days per week. You and your doctor will decide which dosing option works best for you. A KYPROLIS® treatment cycle typically consists of 3 weeks on and 1 week off.
Consider these tips to help you practice good self-care both before and after infusions.
Before your infusion:
After your infusion:
KYPROLIS® works hard to get you through relapse. KYPROLIS® offers 4 different combination treatment regimens. You will work with your doctor to decide which is right for you.
All 4 KYPROLIS® combinations have been proven in clinical studies. The clinical studies evaluated response to treatment and median progression-free survival (the length of time from the start of treatment until half of the people in the clinical study had experienced disease progression or death). Read more about results of each KYPROLIS® combination below.
KYPROLIS® + Darzalex®* + dexamethasone†
Over 8 out of 10 people responded to KYPROLIS® + Darzalex® + dexamethasone.‡
Patients treated with KYPROLIS® + Darzalex® + dexamethasone had a median progression-free survival of 28.6 months vs 15.2 months with Kd alone (84% vs 75% with Kd alone).§
*Darzalex® (daratumumab).
†In a clinical study of 466 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 312 patients received KYPROLIS® in combination with Darzalex® and dexamethasone, and 154 received KYPROLIS® in combination with dexamethasone. The study compared how long patients lived without their disease getting worse. The median follow-up was nearly 28 months.
‡Response was defined as partial response or better.
§In an earlier analysis with a median follow-up of nearly 17 months, the median progression-free survival had not been reached with KYPROLIS® + Darzalex® + dexamethasone vs 15.8 months with Kd alone.
Kd=KYPROLIS® + dexamethasone.
KYPROLIS® + Sarclisa®* + dexamethasone†
Almost 9 out of 10 people responded to KYPROLIS® + Sarclisa® + dexamethasone (87% vs 84% with Kd alone).*,‡
Patients treated with KYPROLIS® + Sarclisa® + dexamethasone had a median progression-free survival of 41.7 months vs 20.8 months with Kd alone.§,**
*Sarclisa® (isatuximab-irfc).
†In a clinical study of 302 people with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 179 people received KYPROLIS® in combination with Sarclisa® and dexamethasone, and 123 received KYPROLIS® in combination with dexamethasone. The study compared how long people lived without their disease getting worse. The median follow-up was 44 months.
‡Response was defined as partial response or better.
§In an earlier analysis with a median follow-up of 21 months, the median progression-free survival had not been reached with KYPROLIS® + Sarclisa® + dexamethasone vs 20.3 months with Kd alone.
**The analysis did not include events occurring > 8 weeks from the last day of disease assessment.
Kd=KYPROLIS® + dexamethasone.
KYPROLIS® + Revlimid®* + dexamethasone†
Almost 9 out of 10 people responded to KYPROLIS® + Revlimid® + dexamethasone (87% vs 67% with Rd alone).*,‡
Patients treated with KYPROLIS® + Revlimid® + dexamethasone had a median progression-free survival of 26.3 months vs 17.6 months with Rd alone.
*Revlimid® (lenalidomide).
†In a clinical study of 792 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 396 patients received KYPROLIS® in combination with Revlimid® and dexamethasone, and 396 received Revlimid® in combination with dexamethasone. The study compared how long patients lived without their disease getting worse as well as how long they lived overall.
‡Response was defined as partial response or better.
Rd=Revlimid® + dexamethasone.
Once-weekly KYPROLIS® + dexamethasone
Over 6 out of 10 people responded to once-weekly KYPROLIS® + dexamethasone (62.9% with once-weekly vs 40.8% with twice-weekly Kd).*,†
Patients treated with once-weekly KYPROLIS® + dexamethasone had a median progression-free survival of 11.2 months vs 7.6 months with twice-weekly KYPROLIS® + dexamethasone.
*In a clinical study of 478 patients with relapsed or refractory multiple myeloma who had received 2 to 3 prior lines of therapy, 240 patients received KYPROLIS® once weekly at 70 mg/m2 in combination with dexamethasone and 238 patients received KYPROLIS® twice weekly at 27 mg/m2 in combination with dexamethasone. The study compared how long patients lived without their disease getting worse.
†Response was defined as partial response or better.
27 mg/m2 is not an FDA-approved dose for KYPROLIS® in combination with dexamethasone alone.
Twice-weekly KYPROLIS® + dexamethasone*
Almost 8 out of 10 people responded to twice-weekly KYPROLIS® + dexamethasone (77% vs 63% with Velcade® + d [Vd]).*,†
Patients treated with twice-weekly KYPROLIS® + dexamethasone had a median progression-free survival of 18.7 months vs 9.4 months with Vd.
*In a clinical study of 929 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy, 464 patients received KYPROLIS® in combination with dexamethasone, and 465 received Velcade® (bortezomib) in combination with dexamethasone. The study compared how long patients lived without their disease getting worse as well as how long they lived overall.
†Response was defined as partial response or better.
Vd=Velcade® + dexamethasone.
KYPROLIS® (carfilzomib) can cause serious side effects:
These are not all the possible side effects of KYPROLIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088